The Role of Rare Protein-Coding Variants in Anti–Tumor Necrosis Factor Treatment Response in Rheumatoid Arthritis

Objective. In many rheumatoid arthritis (RA) patients, disease is controlled with anti–tumor necrosis factor (anti-TNF) biologic therapies. However, in a significant number of patients, the disease fails to respond to anti-TNF therapy. We undertook the present study to examine the hypothesis that rare and low-frequency genetic variants might influence response to anti-TNF treatment. and gene-based association identify variants associated with anti-TNF treatment addition,

[1]  Z. Hussein,et al.  Genetic markers predicting sulphonylurea treatment outcomes in type 2 diabetes patients: current evidence and challenges for clinical implementation , 2016, The Pharmacogenomics Journal.

[2]  A. Julià,et al.  A genome-wide association study identi fi es a new locus associated with the response to anti-TNF therapy in rheumatoid arthritis , 2022 .

[3]  A. Barton,et al.  Impact of Psychological Factors on Subjective Disease Activity Assessments in Patients With Severe Rheumatoid Arthritis , 2014, Arthritis care & research.

[4]  J. Shults,et al.  Development and Validation of Modified Disease Activity Scores in Rheumatoid Arthritis: Superior Correlation With Magnetic Resonance Imaging–Detected Synovitis and Radiographic Progression , 2014, Arthritis & rheumatology.

[5]  Jing Cui,et al.  Genome-Wide Association Study and Gene Expression Analysis Identifies CD84 as a Predictor of Response to Etanercept Therapy in Rheumatoid Arthritis , 2013, PLoS genetics.

[6]  Masa Umicevic Mirkov,et al.  Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis , 2012, Annals of the rheumatic diseases.

[7]  Hideo Tanaka,et al.  Meta-analysis identifies nine new loci associated with rheumatoid arthritis in the Japanese population , 2012, Nature Genetics.

[8]  Robert M. Plenge,et al.  Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis , 2011, Nature Genetics.

[9]  Paul Flicek,et al.  The functional spectrum of low-frequency coding variation , 2011, Genome Biology.

[10]  A. Barton,et al.  Genome-Wide Association Study of Genetic Predictors of Anti–Tumor Necrosis Factor Treatment Efficacy in Rheumatoid Arthritis Identifies Associations with Polymorphisms at Seven Loci , 2011, Arthritis and rheumatism.

[11]  A. Koch.  The pathogenesis of rheumatoid arthritis. , 2007, American journal of orthopedics.

[12]  D. Reich,et al.  Principal components analysis corrects for stratification in genome-wide association studies , 2006, Nature Genetics.

[13]  M. Prevoo,et al.  Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. , 1996, Arthritis and rheumatism.

[14]  M. Prevoo,et al.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[15]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.